US' CDC endorses Covid-19 booster jabs for immunocompromised people

US' Centers for Disease Control and Prevention has endorsed the use of an additional dose of Covid-19 vaccine for people with moderately to severely compromised immune systems

Coronavirus, vaccine, covid-19, vaccination
ANI US
2 min read Last Updated : Aug 14 2021 | 7:42 AM IST

US' Centers for Disease Control and Prevention has endorsed the use of an additional dose of COVID-19 vaccine for people with moderately to severely compromised immune systems after an initial two-dose vaccine series.

In a statement, CDC Director Rochelle P. Walensky said it is an "important step" in ensuring everyone, including those most vulnerable to COVID-19, can get as much protection as possible from COVID-19 vaccination.

While people who are immunocompromised makeup about 3 per cent of the U.S. adult population, they are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness.

"Emerging data suggest some people with moderately to severely compromised immune systems do not always build the same level of immunity compared to people who are not immunocompromised," the statement read.

Included in CDC's recommendation are people with a range of conditions, such as recipients of organ or stem cell transplants, people with advanced or untreated HIV infection, active recipients of treatment for cancer, people who are taking some medications that weaken the immune system, and others.

On Thursday, the FDA said that the agency was unable to extend the authorization for an additional dose to the Johnson & Johnson vaccine due to insufficient data. Representatives of both agencies said they are "actively engaged" to determine the best course of action for recipients of the Johnson & Johnson vaccine.

Earlier this month, the United States rejected an appeal from the World Health Organization for a moratorium on booster shots to help ease the drastic inequity in dose distribution between rich and poor nations.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Aug 14 2021 | 7:42 AM IST

Next Story